GlassScriptPhysician profile
Arthur J Labovitz
NPI 1477572535
$4,615.77
in general payments reported to CMS, 2019-2025
20 companies · $31.00 in 2025
The $31.00 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $16.63 · 2021: $60.95 · 2022: $3,151 · 2023: $977 · 2024: $217 · 2025: $31.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,864.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $744.60 | 2023 | Inpefa |
| Novartis Pharmaceuticals Corporation | $189.73 | 2021-2025 | |
| Abbott Laboratories | $171.74 | 2019-2024 | Mitraclip |
| Philips North America LLC | $149.93 | 2023 | |
| Boston Scientific Corporation | $117.28 | 2023-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.73 | 2024 | Lifevest |
| Pfizer INC. | $51.35 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $46.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.37 | 2022 | |
| Angiodynamics, INC. | $34.62 | 2021 | |
| Alnylam Pharmaceuticals INC. | $24.99 | 2022 | |
| Merck Sharp & Dohme LLC | $18.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.63 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.57 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.66 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Labovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.